What is Automera?
Automera operates at the vanguard of biotechnology, specifically targeting the autophagy process to clear pathogenic proteins and organelles. By utilizing AUTACs, the company aims to revolutionize how clinicians approach complex diseases that have historically resisted conventional pharmacological intervention. Based in Seattle, the firm benefits from a rich ecosystem of life sciences talent and research infrastructure, allowing it to scale its R&D operations effectively. The company's market position is defined by its intellectual property in protein degradation, a high-growth area that has attracted significant interest from both venture capital firms and strategic pharmaceutical partners looking to bolster their pipelines with next-generation therapeutic candidates.
How much funding has Automera raised?
Automera has raised a total of $17M across 2 funding rounds:
Series A
$16M
Debt
$1M
Series A (2023): $16M with participation from Xora Innovation and EDBI
Debt (2026): $1M, investors not publicly disclosed
Key Investors in Automera
Xora Innovation
Xora provides capital and support to deep tech entrepreneurs focused on transforming essential industries, with a specific emphasis on AI in physical industries and engineering.
EDBI
EDBI is a global investor based in Singapore that focuses on high-growth technology sectors, including biotechnology, to catalyze industrial transformation.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Automera?
With the infusion of $1M, Automera is expected to accelerate its preclinical development programs and expand its internal research capabilities. The strategic focus will likely shift toward validating its lead candidates in vivo and establishing key partnerships to facilitate clinical translation. As the company matures, the emphasis will remain on optimizing its AUTAC platform to ensure scalability and safety, which are critical milestones for any biotech firm transitioning from early-stage discovery to clinical-grade development. The ongoing support from its investor base provides the necessary runway to navigate the complex regulatory and scientific hurdles inherent in bringing novel protein-degradation therapies to market.
See full Automera company page
